Yuan, Yong <br/><br/>
Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States.  [electronic resource] 

 -  Journal of medical economics  Mar 2010 
 - 33-41 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1941-837X 
<br/><br/><label>Standard No.: </label>10.3111/13696990903508021  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Abatacept<br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Murine-Derived--economics<br/>Antirheumatic Agents--economics<br/>Cost-Benefit Analysis<br/>Disability Evaluation<br/>Female<br/>Health Status Indicators<br/>Humans<br/>Immunoconjugates--economics<br/>Immunologic Factors--economics<br/>Methotrexate--economics<br/>Middle Aged<br/>Monte Carlo Method<br/>Quality-Adjusted Life Years<br/>Rheumatic Fever--drug therapy<br/>Rituximab<br/>Severity of Illness Index<br/>Surveys and Questionnaires<br/>Tumor Necrosis Factor-alpha--antagonists & inhibitors<br/>United States<br/>Young Adult